111 Capital’s Edwards Lifesciences EW Stock Holding History

111 Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,803	Closed	-$296K	–	403
2025 Q3	$296K	Buy	+3,803	New	+$297K	0.06%	322

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

111 Capital's EW Position: Q4 2025 in Review

111 Capital sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 3,803 shares — an estimated $296K sold.

111 Capital first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $296K in Q3 2025. 1,315 funds tracked by Wall St. Rank hold EW as of Q4 2025.

111 Capital reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
111 Capital sold 3,803 Edwards Lifesciences shares in Q4 2025, an estimated $296K.
111 Capital first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
111 Capital's Edwards Lifesciences position peaked at $296K in Q3 2025.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on 111 Capital's 13F filing for Q4 2025, filed 11 Feb 2026.